U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H62N4O11
Molecular Weight 847.0047
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIFABUTIN

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(C(=O)C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C5NC6(CCN(CC(C)C)CC6)N=C45)C(O)=C3C

InChI

InChIKey=ATEBXHFBFRCZMA-VXTBVIBXSA-N
InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

HIDE SMILES / InChI

Molecular Formula C46H62N4O11
Molecular Weight 847.0047
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/rifabutin.html http://www.rxlist.com/mycobutin-drug.htm http://www.wikidoc.org/index.php/Rifabutin

Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the prophylaxis of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. Multiple dosing of rifabutin has been associated with induction of hepatic metabolic enzymes of the CYP3A subfamily. Rifabutin’s predominant metabolite (25-desacetyl rifabutin: LM565), may also contribute to this effect. Similarly, concomitant medications that competitively inhibit the CYP3A activity may increase plasma concentrations of rifabutin. Common adverse reactions include discoloration of skin, rash, diarrhea, disorder of taste, indigestion, loss of appetite, nausea, vomiting, increased liver aminotransferase level (mild), ocular discoloration, uveitis, abnormal color of body fluid.

CNS Activity

Curator's Comment: Because of frequent side effects at high doses (e.g., arthralgia, uveitis, and stomatitis), rifabutin has rarely been used to treat CNS infections. https://www.ncbi.nlm.nih.gov/pubmed/20930076

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0A8V2
Gene ID: 948488.0
Gene Symbol: rpoB
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MYCOBUTIN

Approved Use

MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
613 ng/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
691 ng/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5803 ng × h/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9287 ng × h/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
58 h
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
45 h
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
21.5%
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFABUTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Other AEs: Abdominal pain, Asthenia...
Other AEs:
Abdominal pain (4%)
Asthenia (1%)
Chest pain (1%)
Fever (2%)
Headache (3%)
Pain (1%)
Anorexia (2%)
Diarrhea (3%)
Dyspepsia (3%)
Eructation (3%)
Flatulence (2%)
Nausea (6%)
Nausea and vomiting (3%)
Vomiting (1%)
Myalgia (2%)
Insomnia (1%)
Rash (11%)
Taste perversion (3%)
Urine discoloration (30%)
Alkaline phosphatase increased (<1%)
SGOT increased (7%)
SGPT increased (9%)
Anemia (6%)
Eosinophilia (1%)
Leukopenia (17%)
Neutropenia (25%)
Thrombocytopenia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Chest pain 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Eosinophilia 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Insomnia 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Pain 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Vomiting 1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Rash 11%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Leukopenia 17%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Anorexia 2%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Fever 2%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Flatulence 2%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Myalgia 2%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Neutropenia 25%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Diarrhea 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Dyspepsia 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Eructation 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Headache 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Nausea and vomiting 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Taste perversion 3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Urine discoloration 30%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Abdominal pain 4%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Thrombocytopenia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Anemia 6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Nausea 6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
SGOT increased 7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
SGPT increased 9%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
Alkaline phosphatase increased <1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 566
Health Status: unhealthy
Condition: Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection
Age Group: adult
Population Size: 566
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
no
no
no
no
no
no
no
unlikely [IC50 31.5 uM]
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes
yes
yes
yes
yes (co-administration study)
Comment: many DDIs: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf#page=3
Drug as victim
PubMed

PubMed

TitleDatePubMed
Rifabutine inhibits HTLV-III.
1986 Jan 11
Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex.
1987
In vitro susceptibility of Mycobacterium avium complex to antibacterial agents.
1987 Nov
In vitro activity of antimicrobial agents against mycobacteria.
1988
Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
1988 Mar
Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare.
1988 Mar-Apr
Qualitative and quantitative drug-susceptibility tests in mycobacteriology.
1988 May
Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro.
1988 May
In vitro effectiveness of a combination of zidovudine and ansamycin against human immunodeficiency virus.
1988 Oct
Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
1988 Oct
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.
1990 Aug
[Activity of azithromycin and roxithromycin alone or in combination against Mycobacterium avium and Mycobacterium xenopi].
1990 May
Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.
1991 Nov-Dec
In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.
1991 Oct
Chlorpromazine: a drug potentially useful for treating mycobacterial infections.
1992
Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
1992 Dec
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
1993 Dec
In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
1993 Jan
In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
1994 May
In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli.
1995 Aug
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis.
1995 Feb
Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
1996 Jun
New ophthalmic manifestations of presumed rifabutin-related uveitis.
1997 Apr
Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method.
1997 Aug
[Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
1998 Feb
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
1998 Jul
Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice.
1999 Fall
In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics.
1999 Nov
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii.
1999 Nov
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
2001 Jan
In vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity.
2002 May
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
2003 Jan
In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
2004 Jul
The activity of grepafloxacin in two murine models of Mycobacterium avium infection.
2004 Jun
Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis.
2005 Dec
Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice.
2007 Mar
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine.
2011 Dec 1
Patents

Sample Use Guides

It is recommended that Rifabutin Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of Rifabutin at doses of 150 mg twice daily taken with food may be useful.
Route of Administration: Oral
In Vitro Use Guide
The IC50 of rifabutin was 26.5 mg/L in a different series of experiments using an enzyme-linked immunoassay and the T. gondii high virulence strain.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:27:37 GMT 2023
Edited
by admin
on Fri Dec 15 16:27:37 GMT 2023
Record UNII
1W306TDA6S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFABUTIN
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
LM-427
Code English
RIFABUTIN [VANDF]
Common Name English
LM 427
Code English
RIFABUTIN [ORANGE BOOK]
Common Name English
MYCOBUTIN
Code English
RIFABUTIN [USP-RS]
Common Name English
ANSAMYCIN
Common Name English
RIFABUTIN [JAN]
Common Name English
RIFABUTIN [EP MONOGRAPH]
Common Name English
RIFABUTIN COMPONENT OF TALICIA
Brand Name English
RIFABUTIN [MI]
Common Name English
1',4-DIDEHYDRO-1-DEOXY-1,4-DIHYDRO-5'-(2-METHYLPROPYL)-1-OXORIFAMYCIN XIV
Common Name English
rifabutin [INN]
Common Name English
Rifabutin [WHO-DD]
Common Name English
4-DEOXO-3,4-(2-SPIRO-(N-ISOBUTYL-4-PIPERIDYL))-(1H)-IMIDAZO-(2,5-DIHYDRO)RIFAMYCIN S
Common Name English
RIFABUTIN [USAN]
Common Name English
TALICIA COMPONENT RIFABUTIN
Brand Name English
4-N-ISOBUTYLSPIROPIPERIDYLRIFAMYCIN S
Common Name English
RIFABUTIN [HSDB]
Common Name English
RIFABUTIN [USP MONOGRAPH]
Common Name English
RIFABUTIN [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ04AB04
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NCI_THESAURUS C280
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
LIVERTOX NBK547975
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
FDA ORPHAN DRUG 41989
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
WHO-ATC J04AB04
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
FDA ORPHAN DRUG 770820
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
NDF-RT N0000175501
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
FDA ORPHAN DRUG 338811
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
FDA ORPHAN DRUG 41889
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
Code System Code Type Description
LACTMED
Rifabutin
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
WIKIPEDIA
RIFABUTIN
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
INN
5668
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
MERCK INDEX
m9608
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY Merck Index
PUBCHEM
6323490
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
RXCUI
55672
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
2376
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
NCI_THESAURUS
C1408
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
MESH
D017828
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
DAILYMED
1W306TDA6S
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
SMS_ID
100000091607
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID0033960
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
EVMPD
SUB10304MIG
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
FDA UNII
1W306TDA6S
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
CHEBI
45367
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
DRUG BANK
DB00615
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
HSDB
3577
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
RS_ITEM_NUM
1603800
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
USAN
FF-8
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
CAS
72559-06-9
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL444633
Created by admin on Fri Dec 15 16:27:37 GMT 2023 , Edited by admin on Fri Dec 15 16:27:37 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY